Angiogenesis inhibitors in cancer therapy: Mechanistic perspective on classification and treatment rationales

British Journal of Pharmacology

Volumn 170, Issue 4, 2013, Pages 712-729

  El Kenawi, Asmaa E ^a   El Remessy, Azza B ^b,c,d  

^a MANSOURA UNIVERSITY   (Egypt)

^b UNIVERSITY OF GEORGIA   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

angiogenesis inhibitors; cancer therapy; tumour micro environment

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; AZD 4547; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CELECOXIB; CILENGITIDE; CYCLOPHOSPHAMIDE; DACINOSTAT; DOCETAXEL; FLUOROURACIL; GOSSYPOL; IBUPROFEN; IMATINIB; ORANTINIB; PACLITAXEL; RABEPRAZOLE; REPARIXIN; SORAFENIB; SUNITINIB; TIPIFARNIB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VATALANIB; VOLOCIXIMAB; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANGIOGENESIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; COLORECTAL CANCER; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; NONHUMAN; ONCOGENE; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; CANCER THERAPY; TUMOUR MICRO-ENVIRONMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG SYNERGISM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TERMINOLOGY AS TOPIC;

EID: 84885106382     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12344     Document Type: Review

References (243)

1. Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ, Debus J, Ansorge W, et al. (2004). Endostatin's antiangiogenic signaling network. Mol Cell 13: 649-663.
2. Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, et al. (2005). Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 11: 6270-6279.
3. Albini A, Tosetti F, Benelli R, Noonan DM, (2005). Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res 65: 10637-10641.
4. Ali TK, El-Remessy AB, (2009). Diabetic retinopathy: current management and experimental therapeutic targets. Pharmacotherapy 29: 182-192.
5. Allen E, Walters IB, Hanahan D, (2011). Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res 17: 5299-5310.
6. Angevin E, Lopez-Martin JA, Lin C-C, Gschwend E Jr, Harzstark A, Castellano D, et al. (2013). Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res 19: 1257-1268.
7. Aplin AE, Howe A, Alahari SK, Juliano RL, (1998). Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev 50: 197-263.
8. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, et al. (2008). HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 451: 1008-1012.
9. Argiris A, Karamouzis MV, Gooding WE, Branstetter BF, Zhong S, Raez LE, et al. (2011). Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 29: 1140-1145.
10. Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, et al. (2013). Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 24: 220-225.
11. Awada A, Eskens FA, Piccart M, Cutler DL, van der Gaast A, Bleiberg H, et al. (2002). Phase I and pharmacological study of the oral farnesyl transferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. Eur J Cancer 38: 2272-2278.
12. Baeriswyl V, Christofori G, (2009). The angiogenic switch in carcinogenesis. Semin Cancer Biol 19: 329-337.
13. Baka S, Clamp AR, Jayson GC, (2006). A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targets 10: 867-876.
14. Balkwill F, Charles KA, Mantovani A, (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217.
15. Banerjee S, Bueso-Ramos C, Aggarwal BB, (2002). Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 62: 4945-4954.
16. Bello E, Taraboletti G, Colella G, Zucchetti M, Forestieri D, Licandro SA, et al. (2013). The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts. Mol Cancer Ther 12: 131-140.
17. Bergers G, Benjamin LE, (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410.
18. Bergers G, Hanahan D, (2008). Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603.
19. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2: 737-744.
20. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. (2006). Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355: 873-884.
21. Besse B, Tsao LC, Chao DT, Fang Y, Soria JC, Almokadem S, et al. (2013). Phase Ib safety and pharmacokinetic study of volociximab, an anti-alpha5beta1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 24: 90-96.
22. Bid HK, Zhan J, Phelps DA, Kurmasheva RT, Houghton PJ, (2011). Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2. Mol Cancer Ther 11: 649-659.
23. Bischoff J, (1997). Cell adhesion and angiogenesis. J Clin Invest 100 (Suppl. 11): S37-S39.
24. Blackhall FH, O'Brien M, Schmid P, Nicolson M, Taylor P, Milenkova T, et al. (2010). A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. J Thorac Oncol 5: 1285-1288.
25. Blaschuk O, Lavoie N, Devamy E, Lepekhin E, (2005). Further observations concerning the effects of the N-cadherin antagonist ExherinTM (ADH-1) on endothelial cells and tumor blood vessels. AACR Meeting Abstracts 2005 (1): 268.
26. Blaschuk OW, (2012). Discovery and development of N-cadherin antagonists. Cell Tissue Res 348: 309-313.
27. Bono F, De Smet F, Herbert C, De Bock K, Georgiadou M, Fons P, et al. (2013). Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell 23: 477-488.
28. Bouis D, Kusumanto Y, Meijer C, Mulder NH, Hospers GAP, (2006). A review on pro- and anti-angiogenic factors as targets of clinical intervention. Pharmacol Res 53: 89-103.
29. Bourboulia D, Stetler-Stevenson WG, (2010). Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 20: 161-168.
30. Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR, (2012). Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. J Natl Cancer Inst 104: 1320-1334.
31. Briasoulis E, Aravantinos G, Kouvatseas G, Pappas P, Biziota E, Sainis I, et al. (2013). Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer 13: 263.
32. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. (2011). Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365: 2473-2483.
33. Burstein HJ, (2011). Bevacizumab for advanced breast cancer: all tied up with a RIBBON? J Clin Oncol 29: 1232-1235.
34. Carmeliet P, (2003). Angiogenesis in health and disease. Nat Med 9: 653-660.
35. Carmeliet P, (2005). Angiogenesis in life, disease and medicine. Nature 438: 932-936.
36. Casanovas O, Hicklin DJ, Bergers G, Hanahan D, (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309.
37. Chapman RW, Phillips JE, Hipkin RW, Curran AK, Lundell D, Fine JS, (2009). CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 121: 55-68.
38. Chen ZY, Shi M, Peng LX, Wei W, Li XJ, Guo ZX, et al. (2012). Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis. J Transl Med 10: 245.
39. Chiu J, Yau T, (2012). Metastatic pancreatic cancer: are we making progress in treatment? Gastroenterol Res Pract 2012: 898931.
40. Chung AS, Lee J, Ferrara N, (2010). Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 10: 505-514.
41. Cirri P, Chiarugi P, (2011). Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res 1: 482-497.
42. Cohen MH, Gootenberg J, Keegan P, Pazdur R, (2007). FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 12: 356-361.
43. Corada M, Zanetta L, Orsenigo F, Breviario F, Lampugnani MG, Bernasconi S, et al. (2002). A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood 100: 905-911.
44. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, et al. (2010). Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 14: 2803-2815.
45. Coussens LM, Fingleton B, Matrisian LM, (2002). Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392.
46. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, et al. (2009). PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15: 21-34.
47. Cui X, Jin Y, Hofseth AB, Pena E, Habiger J, Chumanevich A, et al. (2010). Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev Res (Phila) 3: 549-559.
48. Devy L, Huang L, Naa L, Yanamandra N, Pieters H, Frans N, et al. (2009). Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 69: 1517-1526.
49. Dredge K, Hammond E, Handley P, Gonda TJ, Smith MT, Vincent C, et al. (2011). PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer 104: 635-642.
50. Drevs J, Fakler J, Eisele S, Medinger M, Bing G, Esser N, et al. (2004). Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 24: 1759-1763.
51. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, et al. (2011). Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 6: e20351.
52. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS, (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239.
53. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, et al. (2008). NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68: 2850-2860.
54. Eikesdal HP, Sugimoto H, Birrane G, Maeshima Y, Cooke VG, Kieran M, et al. (2008). Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity. Proc Natl Acad Sci U S A 105: 15040-15045.
55. Elice F, Rodeghiero F, (2010). Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact. Thromb Res 125 (Suppl. 2): S55-S57.
56. Elice F, Rodeghiero F, (2012). Side effects of anti-angiogenic drugs. Thromb Res 129 (Suppl. 1): S50-S53.
57. Ellis LM, Hicklin DJ, (2008). VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8: 579-591.
58. El-Remessy AB, Al-Shabrawey M, Platt DH, Bartoli M, Behzadian MA, Ghaly N, et al. (2007). Peroxynitrite mediates VEGF's angiogenic signal and function via a nitration-independent mechanism in endothelial cells. FASEB J 21: 2528-2539.
59. Evans T, Ramanathan RK, Yazji S, Glynne-Jones R, Anthoney A, Berlin J, et al. (2007). Final results from cohort 1 of a phase II study of volociximab, an anti-{alpha}5{beta}1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC). ASCO Meeting Abstracts 25 (18 Suppl.): 4549.
60. Fabi A, Russillo M, Ferretti G, Metro G, Nistico C, Papaldo P, et al. (2012). Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy. BMC Cancer 12: 482.
61. Fagiani E, Christofori G, (2013). Angiopoietins in angiogenesis. Cancer Lett 328: 18-26.
62. Fang P, Hu JH, Cheng ZG, Liu ZF, Wang JL, Jiao SC, (2012). Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials. PLoS One 7: e49717.
63. Ferrara N, Kerbel RS, (2005). Angiogenesis as a therapeutic target. Nature 438: 967-974.
64. Figlin RA, Kondagunta GV, Yazji S, Motzer RJ, Bukowski RM, (2006). Phase II study of volociximab (M200), an {alpha}5{beta}1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer (RCC). ASCO Meeting Abstracts 24 (18 Suppl.): 4535.
65. Folkman J, (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
66. Folkman J, (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-30.
67. Folkman J, (2003). Angiogenesis and apoptosis. Semin Cancer Biol 13: 159-167.
68. Folkman J, (2007). Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286.
69. Fontana A, Bocci G, Galli L, D'Arcangelo M, Derosa L, Fioravanti A, et al. (2010). Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer. J Am Geriatr Soc 58: 986-988.
70. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. (2002). Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62: 6538-6544.
71. Franco M, Man S, Chen L, Emmenegger U, Shaked Y, Cheung AM, et al. (2006). Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 66: 3639-3648.
72. Fujita M, Khazenzon NM, Ljubimov AV, Lee BS, Virtanen I, Holler E, et al. (2006). Inhibition of laminin-8 in vivo using a novel poly(malic acid)-based carrier reduces glioma angiogenesis. Angiogenesis 9: 183-191.
73. Garofalo A, Naumova E, Manenti L, Ghilardi C, Ghisleni G, Caniatti M, et al. (2003). The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin Cancer Res 9: 3476-3485.
74. Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, et al. (2012). AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 72: 2045-2056.
75. Gaya A, Tse V, (2012). A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev 38: 484-493.
76. Gebbia V, Boussen H, Valerio MR, (2012). Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma. Anticancer Res 32: 529-536.
77. Gerber PA, Hippe A, Buhren BA, Muller A, Homey B, (2009). Chemokines in tumor-associated angiogenesis. Biol Chem 390: 1213-1223.
78. Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L, et al. (2010). Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res 70: 6945-6956.
79. Giantonio BJ, Levy DE, O'Dwyer PJ, Meropol NJ, Catalano PJ, Benson AB, 3rd, (2006). A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 17: 1399-1403.
80. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. (2007). Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544.
81. Giraudo E, Inoue M, Hanahan D, (2004). An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114: 623-633.
82. Giuliani F, De Vita F, Colucci G, Pisconti S, (2010). Maintenance therapy in colon cancer. Cancer Treat Rev 36 (Suppl. 3): S42-S45.
83. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, et al. (1999). Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59: 3374-3378.
84. Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI, et al. (2012). Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 11: 690-699.
85. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, et al. (2004). Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64: 1570-1574.
86. Han JY, Oh SH, Morgillo F, Myers JN, Kim E, Hong WK, et al. (2005). Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 97: 1272-1286.
87. Han LY, Landen CN, Trevino JG, Halder J, Lin YG, Kamat AA, et al. (2006). Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res 66: 8633-8639.
88. Hanahan D, Folkman J, (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
89. Hariharan S, Gustafson D, Holden S, McConkey D, Davis D, Morrow M, et al. (2007). Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol 18: 1400-1407.
90. Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, et al. (2010). Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 28: 1387-1394.
91. Herbert C, Schieborr U, Saxena K, Juraszek J, De Smet F, Alcouffe C, et al. (2013). Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling. Cancer Cell 23: 489-501.
92. Hicklin DJ, Ellis LM, (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027.
93. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, et al. (2008). BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68: 4774-4782.
94. Hillen F, Griffioen AW, (2007). Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 26: 489-502.
95. van Hinsbergh VW, Koolwijk P, (2008). Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc Res 78: 203-212.
96. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. (1999). Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284: 1994-1998.
97. Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, et al. (2005). Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 16: 1391-1397.
98. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N, (1992). Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267: 26031-26037.
99. Hsu C, Yang TS, Huo TI, Hsieh RK, Yu CW, Hwang WS, et al. (2012). Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study. J Hepatol 56: 1097-1103.
100. Hsu JY, Wakelee HA, (2009). Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 23: 289-304.
101. Huang D, Ding Y, Li Y, Luo W-M, Zhang Z-F, Snider J, et al. (2010). Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 70: 1053-1062.
102. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
103. Huveneers S, Truong H, Danen HJ, (2007). Integrins: signaling, disease, and therapy. Int J Radiat Biol 83: 743-751.
104. Ijichi H, Chytil A, Gorska AE, Aakre ME, Bierie B, Tada M, et al. (2011). Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest 121: 4106-4117.
105. Ivy SP, Wick JY, Kaufman BM, (2009). An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 6: 569-579.
106. Izbicka E, Campos D, Carrizales G, Patnaik A, (2005). Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro. Anticancer Res 25: 3215-3223.
107. Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, et al. (2009). Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20: 807-815.
108. Jain RK, (2001). Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-989.
109. Jain RK, (2003). Molecular regulation of vessel maturation. Nat Med 9: 685-693.
110. Jain RK, (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62.
111. Jarvelainen H, Sainio A, Koulu M, Wight TN, Penttinen R, (2009). Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 61: 198-223.
112. Jiang Y, Goldberg ID, Shi YE, (2002). Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21: 2245-2252.
113. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. (2004). Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184-2191.
114. Johnstone KD, Karoli T, Liu L, Dredge K, Copeman E, Li CP, et al. (2010). Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth. J Med Chem 53: 1686-1699.
115. Joyce JA, Pollard JW, (2009). Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-252.
116. Jubb AM, Oates AJ, Holden S, Koeppen H, (2006). Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 6: 626-635.
117. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. (2003). Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65.
118. Kalluri R, Zeisberg M, (2006). Fibroblasts in cancer. Nat Rev Cancer 6: 392-401.
119. Karaca B, Kucukzeybek Y, Gorumlu G, Erten C, Gul MK, Cengiz E, et al. (2008). Profiling of angiogenic cytokines produced by hormone- and drug-refractory prostate cancer cell lines, PC-3 and DU-145 before and after treatment with gossypol. Eur Cytokine Netw 19: 176-184.
120. Karl E, Warner K, Zeitlin B, Kaneko T, Wurtzel L, Jin T, et al. (2005). Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. Cancer Res 65: 5063-5069.
121. Kerbel R, Folkman J, (2002). Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739.
122. Kerbel RS, Viloria-Petit A, Klement G, Rak J, (2000). 'Accidental' anti-angiogenic drugs. Anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 36: 1248-1257.
123. Kim CK, Choi YK, Lee H, Ha KS, Won MH, Kwon YG, et al. (2010). The farnesyltransferase inhibitor LB42708 suppresses vascular endothelial growth factor-induced angiogenesis by inhibiting ras-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signal pathways. Mol Pharmacol 78: 142-150.
124. Kim R, Emi M, Arihiro K, Tanabe K, Uchida Y, Toge T, (2005). Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. Cancer 103: 1800-1809.
125. Kimura Y, Okuda H, (2001). Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J Nutr 131: 1844-1849.
126. Klenke FM, Abdollahi A, Bertl E, Gebhard MM, Ewerbeck V, Huber PE, et al. (2007). Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo. BMC Cancer 7: 49.
127. Kreisl TN, McNeill KA, Sul J, Iwamoto FM, Shih J, Fine HA, (2012). A phase I/II trial of vandetanib for patients with recurrent malignant glioma. Neuro Oncol 14: 1519-1526.
128. Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi K, Shibuya M, et al. (2009). M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med 206: 1089-1102.
129. Lammerts E, Roswall P, Sundberg C, Gotwals PJ, Koteliansky VE, Reed RK, et al. (2002). Interference with TGF-beta1 and -beta3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma. Int J Cancer 102: 453-462.
130. Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke MH, et al. (2007). Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther 6: 1123-1132.
131. Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, et al. (2012). Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 13: 897-905.
132. Ledermann JA, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I, et al. (2011). Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 29: 3798-3804.
133. Lee J, (2013). Hypoxia-inducible Factor-1 (HIF-1)-independent hypoxia response of the small heat shock protein hsp-16.1 gene regulated by chromatin-remodeling factors in the nematode Caenorhabditis elegans. J Biol Chem 288: 1582-1589.
134. Lee JS, Hirsh V, Park K, Qin S, Blajman CR, Perng RP, et al. (2012). Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 30: 1114-1121.
135. Leek RD, Talks KL, Pezzella F, Turley H, Campo L, Brown NS, et al. (2002). Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res 62: 1326-1329.
136. Leenders WP, Kusters B, de Waal RM, (2002). Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis. Endothelium 9: 83-87.
137. Lewis CE, Pollard JW, (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605-612.
138. Li D, Williams JI, Pietras RJ, (2002). Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. Oncogene 21: 2805-2814.
139. Li WW, Li VW, Hutnik M, Chiou AS, (2012). Tumor angiogenesis as a target for dietary cancer prevention. J Oncol 2012: 879623.
140. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, et al. (2006). Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66: 11238-11246.
141. Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, et al. (2009). Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 50: 958-968.
142. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
143. Loges S, Schmidt T, Carmeliet P, (2010). Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 1: 12-25.
144. Lopez-Lopez C, LeRoith D, Torres-Aleman I, (2004). Insulin-like growth factor I is required for vessel remodeling in the adult brain. Proc Natl Acad Sci U S A 101: 9833-9838.
145. Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, et al. (2007). Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 177: 2136-2140; discussion 2140.
146. Lorusso G, Ruegg C, (2008). The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 130: 1091-1103.
147. Ma J, Waxman DJ, (2008). Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 7: 3670-3684.
148. Ma J, Waxman DJ, (2009). Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib. Clin Cancer Res 15: 578-588.
149. Ma J, Chen CS, Blute T, Waxman DJ, (2011). Antiangiogenesis enhances intratumoral drug retention. Cancer Res 71: 2675-2685.
150. MacLauchlan S, Yu J, Parrish M, Asoulin TA, Schleicher M, Krady MM, et al. (2011). Endothelial nitric oxide synthase controls the expression of the angiogenesis inhibitor thrombospondin 2. Proc Natl Acad Sci U S A 108: E1137-E1145.
151. Maeshima Y, Sudhakar A, Lively JC, Ueki K, Kharbanda S, Kahn CR, et al. (2002). Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295: 140-143.
152. Manegold C, Vansteenkiste J, Cardenal F, Schuette W, Woll PJ, Ulsperger E, et al. (2013). Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer. Invest New Drugs 31: 175-182.
153. Manegold PC, Paringer C, Kulka U, Krimmel K, Eichhorn ME, Wilkowski R, et al. (2008). Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res 14: 892-900.
154. Manthey CL, Johnson DL, Illig CR, Tuman RW, Zhou Z, Baker JF, et al. (2009). JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther 8: 3151-3161.
155. Martens E, Leyssen A, Van Aelst I, Fiten P, Piccard H, Hu J, et al. (2007). A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains. Biochim Biophys Acta 1770: 178-186.
156. Matsuo Y, Sawai H, Ochi N, Yasuda A, Sakamoto M, Takahashi H, et al. (2009). Proteasome inhibitor MG132 inhibits angiogenesis in pancreatic cancer by blocking NF-kappaB activity. Dig Dis Sci 55: 1167-1176.
157. May C, Doody JF, Abdullah R, Balderes P, Xu X, Chen CP, et al. (2005). Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature. Blood 105: 4337-4344.
158. Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, et al. (2012). Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One 7: e38231.
159. Minor DR, (2012). Bevacizumab advanced melanoma (BEAM) was a positive trial. J Clin Oncol 30: 2023; author reply 2023-2024.
160. Mizukami Y, Kohgo Y, Chung DC, (2007). Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res 13: 5670-5674.
161. Montero AJ, Escobar M, Lopes G, Gluck S, Vogel C, (2012). Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr Oncol Rep 14: 1-11.
162. Moser C, Lang SA, Hackl C, Wagner C, Scheiffert E, Schlitt HJ, et al. (2012). Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. Anticancer Res 32: 2551-2561.
163. Mueller J, Gaertner FC, Blechert B, Janssen KP, Essler M, (2009). Targeting of tumor blood vessels: a phage-displayed tumor-homing peptide specifically binds to matrix metalloproteinase-2-processed collagen IV and blocks angiogenesis in vivo. Mol Cancer Res 7: 1078-1085.
164. Mundel TM, Kalluri R, (2007). Type IV collagen-derived angiogenesis inhibitors. Microvasc Res 74: 85-89.
165. Murakami M, (2011). Lipid mediators in life science. Exp Anim 60: 7-20.
166. Murakami M, Nguyen LT, Hatanaka K, Schachterle W, Chen P-Y, Zhuang ZW, et al. (2011). FGF-dependent regulation of VEGF receptor 2 expression in mice. J Clin Invest 121: 2668-2678.
167. Murdoch C, Muthana M, Coffelt SB, Lewis CE, (2008). The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8: 618-631.
168. Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K, et al. (2008). Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci U S A 105: 9343-9348.
169. Nagy JA, Feng D, Vasile E, Wong WH, Shih SC, Dvorak AM, et al. (2006). Permeability properties of tumor surrogate blood vessels induced by VEGF-A. Lab Invest 86: 767-780.
170. Nakashima T, Huang C, Liu D, Kameyama K, Masuya D, Kobayashi S, et al. (2003). Neural-cadherin expression associated with angiogenesis in non-small-cell lung cancer patients. Br J Cancer 88: 1727-1733.
171. Naumova E, Ubezio P, Garofalo A, Borsotti P, Cassis L, Riccardi E, et al. (2006). The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clin Cancer Res 12: 1839-1849.
172. Navid F, Baker SD, McCarville MB, Stewart CF, Billups CA, Wu J, et al. (2013). Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. Clin Cancer Res 19: 236-246.
173. Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, et al. (2002). Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 1: 1243-1253.
174. Nelius T, Rinard K, Filleur S, (2011). Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature. Cancer Treat Rev 37: 444-455.
175. Nyberg P, Xie L, Kalluri R, (2005). Endogenous inhibitors of angiogenesis. Cancer Res 65: 3967-3979.
176. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285.
177. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. (2011). Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29: 3968-3976.
178. Pang X, Wu Y, Lu B, Chen J, Wang J, Yi Z, et al. (2011). (-)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis. Mol Cancer Ther 10: 795-805.
179. Papageorgiou A, Kamat A, Benedict WF, Dinney C, McConkey DJ, (2006). Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther 5: 3032-3041.
180. Penel N, Adenis A, Bocci G, (2012). Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going? Crit Rev Oncol Hematol 82: 40-50.
181. Polverini PJ, (2002). Angiogenesis in health and disease: insights into basic mechanisms and therapeutic opportunities. J Dent Educ 66: 962-975.
182. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M, (2005). Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 16: 159-178.
183. Pugh CW, Ratcliffe PJ, (2003). Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9: 677-684.
184. Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, et al. (2004). The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 64: 6626-6634.
185. Qin L, Zhao D, Xu J, Ren X, Terwilliger EF, Parangi S, et al. (2013). The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1. Blood 121: 2154-2164.
186. Reardon DA, Cheresh D, (2011). Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer 2: 1159-1165.
187. Ribatti D, (2009). Endogenous inhibitors of angiogenesis: a historical review. Leuk Res 33: 638-644.
188. Ribatti D, Djonov V, (2012). Intussusceptive microvascular growth in tumors. Cancer Lett 316: 126-131.
189. Rogers TL, Holen I, (2011). Tumour macrophages as potential targets of bisphosphonates. J Transl Med 9: 177.
190. Roskoski R, Jr, (2007). Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 356: 323-328.
191. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. (2010). Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376: 1741-1750.
192. Rudge JS, Holash J, Hylton D, Russell M, Jiang S, Leidich R, et al. (2007). VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A 104: 18363-18370.
193. Ruoslahti E, Bhatia SN, Sailor MJ, (2010). Targeting of drugs and nanoparticles to tumors. J Cell Biol 188: 759-768.
194. Sabbadini RA, (2011). Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration. Br J Pharmacol 162: 1225-1238.
195. Sanderson S, Valenti M, Gowan S, Patterson L, Ahmad Z, Workman P, et al. (2006). Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol Cancer Ther 5: 522-532.
196. Santini D, Vespasiani Gentilucci U, Vincenzi B, Picardi A, Vasaturo F, La Cesa A, et al. (2003). The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14: 1468-1476.
197. Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, et al. (2007). Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 13 (15 Pt 1): 4482-4486.
198. Schuster C, Eikesdal HP, Puntervoll H, Geisler J, Geisler S, Heinrich D, et al. (2012). Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS One 7: e38364.
199. Schwartz EL, (2009). Antivascular actions of microtubule-binding drugs. Clin Cancer Res 15: 2594-2601.
200. Shahrzad S, Shirasawa S, Sasazuki T, Rak JW, Coomber BL, (2008). Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts. Oncogene 27: 3729-3738.
201. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, et al. (2006). Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313: 1785-1787.
202. Shinohara ET, Cao C, Niermann K, Mu Y, Zeng F, Hallahan DE, et al. (2005). Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 24: 5414-5422.
203. Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, et al. (2007). Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450: 825-831.
204. Shojaei F, Singh M, Thompson JD, Ferrara N, (2008). Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A 105: 2640-2645.
205. Stacchiotti S, Negri T, Zaffaroni N, Palassini E, Morosi C, Brich S, et al. (2011). Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol 22: 1682-1690.
206. Stathopoulos GT, Moschos C, Loutrari H, Kollintza A, Psallidas I, Karabela S, et al. (2008). Zoledronic acid is effective against experimental malignant pleural effusion. Am J Respir Crit Care Med 178: 50-59.
207. Strieter RM, Belperio JA, Phillips RJ, Keane MP, (2004). CXC chemokines in angiogenesis of cancer. Semin Cancer Biol 14: 195-200.
208. Summy JM, Trevino JG, Lesslie DP, Baker CH, Shakespeare WC, Wang Y, et al. (2005). AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol Cancer Ther 4: 1900-1911.
209. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al. (2001). Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7: 1419-1428.
210. Taeger J, Moser C, Hellerbrand C, Mycielska ME, Glockzin G, Schlitt HJ, et al. (2011). Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther 10: 2157-2167.
211. Takahashi H, Shibuya M, (2005). The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci 109: 227-241.
212. Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P, et al. (2005). Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 65: 3193-3199.
213. Tei K, Kawakami-Kimura N, Taguchi O, Kumamoto K, Higashiyama S, Taniguchi N, et al. (2002). Roles of cell adhesion molecules in tumor angiogenesis induced by cotransplantation of cancer and endothelial cells to nude rats. Cancer Res 62: 6289-6296.
214. Teicher BA, (1996). A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics - >mechanism(s) of interaction). Cancer Metastasis Rev 15: 247-272.
215. di Tomaso E, London N, Fuja D, Logie J, Tyrrell JA, Kamoun W, et al. (2009). PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment. PLoS One 4: e5123.
216. Ton GN, Banaszynski ME, Kolesar JM, (2013). Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer. Am J Health Syst Pharm 70: 849-855.
217. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK, (2004). Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64: 3731-3736.
218. Trepel J, Mollapour M, Giaccone G, Neckers L, (2010). Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10: 537-549.
219. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN, (1998). Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716.
220. Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, et al. (2012). Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 30: 2119-2127.
221. Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Hegmans JP, et al. (2010). Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. Br J Cancer 103: 629-641.
222. Vergote IB, Colombo N, Kutarska E, Del Campo J, Pippitt C, Casado A, et al. (2009). Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer. ASCO Meeting Abstracts 27 (15S): 5560.
223. Verheul HM, Pinedo HM, (2007). Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7: 475-485.
224. Vermorken JB, Guigay J, Mesia R, Trigo JM, Keilholz U, Kerber A, et al. (2012). Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer 104: 1691-1696.
225. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, et al. (2006). Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9: 225-238.
226. Vlodavsky I, Friedmann Y, (2001). Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108: 341-347.
227. Wang D, Dubois RN, (2010). Eicosanoids and cancer. Nat Rev Cancer 10: 181-193.
228. Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, et al. (2006). CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 203: 941-951.
229. Wang L, Park H, Chhim S, Ding Y, Jiang W, Queen C, et al. (2012). A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts. Mol Cancer Ther 11: 864-872.
230. Wang Z, Song W, Aboukameel A, Mohammad M, Wang G, Banerjee S, et al. (2008). TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer. Int J Cancer 123: 958-966.
231. Wang Z, Chui WK, Ho PC, (2011). Nanoparticulate delivery system targeted to tumor neovasculature for combined anticancer and antiangiogenesis therapy. Pharm Res 28: 585-596.
232. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, et al. (2002). ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62: 4645-4655.
233. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL, Xie K, (2004). Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 64: 2030-2038.
234. Weis SM, Cheresh DA, (2011). Alphav integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med 1: a006478.
235. Wells SA, Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. (2012). Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30: 134-141.
236. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA, (1996). The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 271: 10079-10086.
237. Willis LM, El-Remessy AB, Somanath PR, Deremer DL, Fagan SC, (2011). Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence. Clin Sci 120: 307-319.
238. Yao M, Zhou W, Sangha S, Albert A, Chang AJ, Liu TC, et al. (2005). Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res 11: 1618-1628.
239. Yoshikawa D, Ojima H, Kokubu A, Ochiya T, Kasai S, Hirohashi S, et al. (2009). Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer 100: 1257-1266.
240. Zhang CC, Yan Z, Zhang Q, Kuszpit K, Zasadny K, Qiu M, et al. (2010). PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity. Clin Cancer Res 16: 5177-5188.
241. Zhao G, Li W-Y, Chen D, Henry JR, Li H-Y, Chen Z, et al. (2011). A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther 10: 2200-2210.
242. Zhao WM, Wang L, Park H, Chhim S, Tanphanich M, Yashiro M, et al. (2010). Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts. Clin Cancer Res 16: 5750-5758.
243. Zhou H, Roy S, Cochran E, Zouaoui R, Chu CL, Duffner J, et al. (2011). M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS One 6: e21106.